SV-102

DRUG2 trials

Sponsors

Williams Cancer Foundation, Syncromune, Inc.

Conditions

Metastatic Castration-resistant Prostate Cancer

Phase 1

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

CompletedNCT05544227

Williams Cancer FoundationMetastatic Castration-resistant Prostate Cancer

Start: 2023-02-01End: 2025-06-01Updated: 2025-07-23

Phase 2

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

RecruitingNCT06533644

Syncromune, Inc.Metastatic Castration-resistant Prostate Cancer

Start: 2025-05-29End: 2028-04-14Target: 91Updated: 2026-06-23

Related Papers

Clinical responses to SYNC-T therapy: In situ personalized cancer vaccination with intratumoral immunotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC).

Journal of Clinical Oncology2025-05-28